Advisors Capital Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $46.2M | Buy |
38,507
+29,000
| +305% | +$29.6M | 0.49% | 62 |
|
|
2026
Q1 | $8.74M | Sell |
9,507
-150
| -2% | -$152K | 0.1% | 173 |
|
|
2025
Q4 | $10.4M | Sell |
9,657
-894
| -8% | -$855K | 0.12% | 165 |
|
|
2025
Q3 | $8.05M | Buy |
10,551
+630
| +6% | +$469K | 0.1% | 176 |
|
|
2025
Q2 | $7.73M | Sell |
9,921
-726
| -7% | -$564K | 0.11% | 170 |
|
|
2025
Q1 | $8.79M | Buy |
10,647
+254
| +2% | +$211K | 0.14% | 152 |
|
|
2024
Q4 | $8.02M | Buy |
10,393
+5,254
| +102% | +$4.35M | 0.13% | 159 |
|
|
2024
Q3 | $4.55M | Sell |
5,139
-829
| -14% | -$745K | 0.07% | 195 |
|
|
2024
Q2 | $5.4M | Sell |
5,968
-1,302
| -18% | -$1.04M | 0.09% | 177 |
|
|
2024
Q1 | $5.66M | Buy |
7,270
+1,342
| +23% | +$955K | 0.1% | 175 |
|
|
2023
Q4 | $3.46M | Buy |
5,928
+616
| +12% | +$360K | 0.07% | 209 |
|
|
2023
Q3 | $2.85M | Buy |
5,312
+235
| +5% | +$121K | 0.07% | 194 |
|
|
2023
Q2 | $2.38M | Buy |
5,077
+368
| +8% | +$154K | 0.06% | 209 |
|
|
2023
Q1 | $1.62M | Sell |
4,709
-362
| -7% | -$122K | 0.04% | 222 |
|
|
2022
Q4 | $1.86M | Buy |
5,071
+422
| +9% | +$150K | 0.05% | 214 |
|
|
2022
Q3 | $1.66M | Buy |
4,649
+58
| +1% | +$18.4K | 0.04% | 226 |
|
|
2022
Q2 | $1.49M | Sell |
4,591
-57
| -1% | -$17.1K | 0.05% | 230 |
|
|
2022
Q1 | $1.33M | Buy |
4,648
+12
| +0.3% | +$3.09K | 0.04% | 225 |
|
|
2021
Q4 | $1.28M | Buy |
4,636
+236
| +5% | +$59.8K | 0.03% | 230 |
|
|
2021
Q3 | $1.02M | Buy |
4,400
+160
| +4% | +$39.5K | 0.03% | 235 |
|
|
2021
Q2 | $973K | Buy |
4,240
+139
| +3% | +$27.9K | 0.03% | 235 |
|
|
2021
Q1 | $766K | Buy |
4,101
+776
| +23% | +$152K | 0.03% | 243 |
|
|
2020
Q4 | $561K | Buy |
3,325
+56
| +2% | +$8.36K | 0.02% | 257 |
|
|
2020
Q3 | $484K | Buy |
3,269
+350
| +12% | +$54.2K | 0.02% | 234 |
|
|
2020
Q2 | $479K | Buy |
2,919
+119
| +4% | +$18.3K | 0.02% | 225 |
|
|
2020
Q1 | $388K | Sell |
2,800
-25
| -0.9% | -$3.44K | 0.02% | 220 |
|
|
2019
Q4 | $371K | Buy |
2,825
+9
| +0.3% | +$1.04K | 0.02% | 277 |
|
|
2019
Q3 | $315K | Buy |
2,816
+90
| +3% | +$10K | 0.02% | 257 |
|
|
2019
Q2 | $302K | Sell |
2,726
-1
| -0% | -$118 | 0.02% | 245 |
|
|
2019
Q1 | $352K | Buy |
2,727
+365
| +15% | +$44.4K | 0.02% | 230 |
|
|
2018
Q4 | $273K | Buy |
+2,362
| New | +$264K | 0.02% | 245 |
|
Other funds holding LLY
Advisors Capital Management's LLY Position: Q2 2026 in Review
Advisors Capital Management increased its Eli Lilly (LLY) stake by 305% in Q2 2026, buying an estimated $29.6M and bringing the position to 38,507 shares worth $46.2M. The position accounts for 0.49% of the portfolio, ranked #62.
Advisors Capital Management first reported a position in LLY in Q4 2018 and has held it in 31 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Advisors Capital Management held 38,507 shares of Eli Lilly worth $46.2M as of Q2 2026.
- Advisors Capital Management bought 29,000 Eli Lilly shares in Q2 2026, an estimated $29.6M.
- Eli Lilly made up 0.49% of Advisors Capital Management's portfolio in Q2 2026, its #62 holding.
- Advisors Capital Management first reported a position in Eli Lilly in Q4 2018 and has held it in 31 quarters since.
- 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.